Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

In 101 patients with refractory large B-cell lymphoma, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy (axicabtagene ciloleucel) resulted in an overall response rate of 82%, with a 52% survival at 18 months, despite serious toxic effects.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2017-12, Vol.377 (26), p.2531-2544
Hauptverfasser: Neelapu, Sattva S, Locke, Frederick L, Bartlett, Nancy L, Lekakis, Lazaros J, Miklos, David B, Jacobson, Caron A, Braunschweig, Ira, Oluwole, Olalekan O, Siddiqi, Tanya, Lin, Yi, Timmerman, John M, Stiff, Patrick J, Friedberg, Jonathan W, Flinn, Ian W, Goy, Andre, Hill, Brian T, Smith, Mitchell R, Deol, Abhinav, Farooq, Umar, McSweeney, Peter, Munoz, Javier, Avivi, Irit, Castro, Januario E, Westin, Jason R, Chavez, Julio C, Ghobadi, Armin, Komanduri, Krishna V, Levy, Ronald, Jacobsen, Eric D, Witzig, Thomas E, Reagan, Patrick, Bot, Adrian, Rossi, John, Navale, Lynn, Jiang, Yizhou, Aycock, Jeff, Elias, Meg, Chang, David, Wiezorek, Jeff, Go, William Y
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Antigens, CD19
B-cell lymphoma
Biomarkers - blood
Body weight
Cancer therapies
CD19 antigen
Chemotherapy
Chimeric antigen receptors
Clinical trials
Cyclophosphamide
Cytokines
Disease-Free Survival
Drug dosages
Female
Fludarabine
Humans
Immunotherapy, Adoptive
Interleukins - blood
Lymphocytes
Lymphocytes B
Lymphocytes T
Lymphoma
Lymphoma, Large B-Cell, Diffuse - mortality
Lymphoma, Large B-Cell, Diffuse - therapy
Male
Medical prognosis
Middle Aged
Myelosuppression
Nervous System Diseases - chemically induced
Neutropenia
Neutropenia - chemically induced
Patients
Receptors, Antigen, T-Cell - blood
Receptors, Antigen, T-Cell - therapeutic use
Survival Rate
T-Lymphocytes - immunology
T-Lymphocytes - transplantation
Thrombocytopenia
Young Adult
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In 101 patients with refractory large B-cell lymphoma, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy (axicabtagene ciloleucel) resulted in an overall response rate of 82%, with a 52% survival at 18 months, despite serious toxic effects.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1707447